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ischaemic stroke (PC Trial only). Patients were randomly assigned to PFO closure or to medical therapy. The trial end points included death, nonfatal stroke, TIA or peripheral embolism.
Both trials followed the 909-patient CLOSURE I trial, 9 which suggested no benefit of PFO closure over medical therapy for stroke or TIA prevention. The PC Trial (414 patients) also failed to show a benefit of PFO closure. 5 In the RESPECT trial (980 patients), no significant benefit of PFO closure was observed in the primary intention-to-treat analysis, but closure was superior to medical therapy in the perprotocol and as-treated analyses. 4 Taken together, the CLOSURE I, RESPECT and PC Trials are unlikely to convince sceptics of the benefits of PFO closure in patients with cryptogenic stroke, although RESPECT provides a potential positive signal that could be investigated further given the equipoise between percutaneous intervention and medical treatment.
Neuroprotection for AIS is defined as a therapy aimed at enhancing the brain's resilience to ischaemia to improve clinical outcome. Half a century of neuroprotection research has failed to translate over 1,000 experimental treatments to clinical utility, 10 but the ENACT trial 6 might have finally provided a positive signal. ENACT explored whether administration of the PSD95 inhibitor NA-1 (also known as TatNR2B9c) 8 after stroke onset could reduce ischaemic brain damage in patients undergoing endovascular brain aneurysm repair. Such individuals have a high incidence of small procedurally induced ischaemic strokes. 185 participants were enrolled in a multicentre, randomized, double-blinded trial, and received a single intravenous infusion of NA-1 or saline (as a control) after the endovascular procedure. Patients who received NA-1 sustained markedly fewer ischaemic infarcts, as gauged by MRI. Among those patients with ruptured aneurysms, NA-1 reduced the number and volume of strokes and improved neurological outcome at 30 days. This trial provides the first evidence that neuroprotection in the ischaemic human brain is feasible and measurable, and sets the stage for future trials to improve AIS outcomes via monotherapy or in combination with recanalization strategies.
The past year has provided a sobering reminder of the challenge of subjecting stroke interventions to rigorous scientific scrutiny, even when they are intuitively accepted in common medical practice. Nonetheless, each advance discussed above contributes to future studies in stroke research, and aids improvement of outcomes for patients with stroke. 
NEURO-ONCOLOGY IN 2013
Improving outcome in newly diagnosed malignant glioma
Michael Weller and Wolfgang Wick
In 2013, two discoveries-that alkylating agent chemotherapy prolongs survival when added to radiotherapy for patients with anaplastic oligodendroglial tumours with 1p19q codeletion, and that bevacizumab prolongs progression-free survival in patients with newly diagnosed glioblastoma-have dominated debate in neuro-oncology. These findings could help to define new standards of care in malignant glioma. 
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Therapy Oncology Group (RTOG) 9402-demonstrated a major increase in median survival when procarbazine, lomustine and vincristine (a combination termed PCV) were added to radiotherapy in patients with newly diagnosed anaplastic oligodendro glial tumours with 1p19q codeletions.
4,5 These findings contrast with the initial reports from 2006, which indicated no significant difference in outcome between radiotherapy and combined-modality treatment. This discrepancy is perhaps best explained by the existence of two or more distinct subgroups of patients within the cohort of patients with 1p19q-codeleted tumours, with one subgroup being less chemotherapy-responsive with a less favourable course, and another being alkylator-sensitive with longer survival overall. Of note, subgroups of patients with as yet molecularly undefined tumours in the cohort with 1p19q-intact tumours also seemed to benefit from combination therapy.
Although these observations are largely exploratory and stem from clinical trials that were insufficiently powered for such subgroup analyses, the similarities in outcome in two independent trials are remarkable. Even before prospective validation, the relevance of these results to patients has been deemed sufficient to prompt changes both in clinical practice and in the current transatlantic clinical trial portfolio. Radiotherapy alone should no longer be considered the standard of care in patients with 1p19q-codeleted anaplastic oligodendroglial tumours. The design of the ongoing CODEL trial (NCT00887146), which originally set out to compare the effects of radiotherapy alone, TMZ/RT→TMZ, and TMZ alone in patients with 1p19q-codeleted anaplastic glioma, has also been modified in light of the new data. The revised CODEL trial will compare radio therapy plus PCV with TMZ/ RT→TMZ or TMZ alone. Long-term followup data from NOA-04, the third relevant anaplastic glioma trial, which is comparing radiotherapy alone with chemotherapy (TMZ or PCV) alone, 6 may soon indicate whether the hope for improved long-term control by alkylating agent chemotherapy alone is justified, and should help to validate 1p19q codeletion as a predictive biomarker.
Trials in anaplastic glioma are increasingly challenging because of the demanding logistics and funding required for molecular profiling and long-term follow-up, and new insights from molecular studies require continual reconsideration of our clinical research strategies. We propose that for clinical trials at least, the distinction between IDH1/2-mutant and IDH1/2-wildtype tumours should override the distinction between WHO grade II, III and IV tumours, and provide guidance for clinical practice (Figure 1 ).
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Another major debate in neuro-oncology in 2013 focused on the clinical impact of the AVAglio and RTOG 0825 trials, which explored the efficacy of bevacizumab-a monoclonal antibody targeting vascular endothelial growth factor (VEGF)-in the treatment of newly diagnosed glioblastoma. 8, 9 Efficacy outcomes were similar between the two trials: progression-free survival was prolonged by 3-4 months, but overall survival did not improve. Owing to differences in statistical design, the gain in progression-free survival reached statistical significance in AVAglio, but not in RTOG 0825. No particular subgroups, as defined by age, extent of resection or MGMT promoter methylation status, derived preferential benefits from bevacizumab. In addition, a molecular signature predicting beneficial versus detrimental effects of bevacizumab on overall survival, as proposed by RTOG, requires validation.
Safety and tolerability data were comparable between the two trials, but observations on cognitive function and quality of life were contradictory. AVAglio reported decreased steroid use and preserved quality of life with bevacizumab until progression, whereas RTOG 0825 reported decline in various domains of cognition and quality of life in bevacizumab-treated patients before progression. The test batteries were similar, but the time points differed, and testing was enforced by the protocol to a greater extent in AVAglio than in RTOG 0825. Central review of neuro imaging in AVAglio seemed to rule out diffuse, nonenhancing disease progression as an explanation for early cognitive decline in bevacizumab-treated patients. While the exploratory analysis of the-albeit uncontrolled-BRAIN trial of single-agent bevacizumab in recurrent glioblastoma revealed improvement in health-related quality of life and cognitive function, 10 the possibility of adverse interactions between bevacizumab and radiotherapy remains.
Owing to the lack of a survival gain, and the possibility of adverse effects on cognitive function and quality of life, the use of bevacizumab in newly diagnosed glioblastoma may be most attractive in patients ■ Current controversies on clinical benefit versus safety and toxicity of bevacizumab require further well-designed, prospective clinical trials
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with a low chance of benefiting from standard radiochemo therapy; that is, those who have large tumours lacking MGMT promoter methylation, and are unlikely to receive salvage therapies at progression. These subgroups of patients were underrepresented in AVAglio and RTOG 0825, and probably include a large proportion of the increasing population of elderly patients with glioblastoma. Controlled trials such as EORTC 26101 (NCT01290939) are required to define the role of bevacizumab in recurrent glioblastoma. Biomarkers to predict primary resistance to VEGF inhibition and to identify the biochemical escape pathways from such treatments are urgently needed to better define the role-if any-of VEGF inhibitors in glioma treatment. Following the failure of three rival anti-angiogenic agents, enzastaurin, cediranib and cilengitide, in glioblastoma, we cannot yet conclude whether AVAglio and RTOG 0825 herald the end of, or a new beginning for, the era of anti-angiogenic therapy for malignant glioma.
The neuro-oncology field is making great progress in improving the molecular subclassification of gliomas, and the first molecular biomarkers for clinical decision-making are entering clinical practice. In 2013, individualized cancer care has become a reality for many patients with brain tumours. The main challenges for patients with anaplastic gliomas will be the implementation of molecular testing in day-to-day practice, improvement of outcome in the poor-prognosis group, and development of new surrogate end points for earlier assessment of success in patients with progression-free survival of many years. For anti-angiogenic treatments, the best position-first-line or recurrencefor anti-VEGF treatment remains to be defined, as do the molecularly defined subgroups who are most likely to benefit from this treatment. More importantly, anti-angiogenic agents acting beyond the VEGF-VEGF receptor pathway, and combinations that also aim to kill tumour cells, await development.
